SAM-e

Videos

Benefits of SAMe:

Doctor's Best: Sam-E Supplement Review (Mood Enhancer)

Jarrow Formulas SAM-e 200mg Honest Review

What does it mean if you're helped by SAMe?

If I use SAMe for depression, what do I need for nutritional balance?

Trimethylglycine / Betaine can increase SAM-e by remethylating homocysteine.

SAMe is a chemical that is found naturally in the body. It can also be made in the laboratory.

SAMe has been available as a dietary supplement in the US since 1999, but it has been used as a prescription drug in Italy since 1979, in Spain since 1985, and in Germany since 1989. Researchers discovered the potential usefulness of SAMe for treating osteoarthritis by accident. They were studying SAMe’s effect on depression when the patients they were following reported an unexpected improvement in their osteoarthritis symptoms.

SAMe is used for depression, anxiety, heart disease, fibromyalgia, osteoarthritis,bursitis, tendonitis, chronic lower back pain, dementia, Alzheimer's disease, slowing the aging process, chronic fatigue syndrome (CFS), improving intellectual performance, liver disease, and Parkinson's disease. It is also used for attention deficit-hyperactivity disorder (ADHD), multiple sclerosis, spinal cord injury, seizures,migraine headache, and lead poisoning.

Some women use SAMe for premenstrual syndrome (PMS) and a more severe form of PMS called premenstrual dysphoric disorder (PMDD).

How does it work?

The body uses SAMe to make certain chemicals in the body that play a role in pain, depression, liver disease, and other conditions. People who don’t make enough SAMe naturally may be helped by taking SAMe as a supplement.

Dose;

In depression, 800 mg twice a day

USES

To treat arthritis

A few studies show that SAM-e is as effective as conventional treatments in treating osteoarthritis.

To treat chronic liver disease

Earlier studies found SAM-e helpful in chronic liver disease, but additional studies are needed to confirm this.

To treat drug-induced liver toxicity

Initial studies suggest that SAM-e may help reduce liver toxicity caused by some drugs, but more studies are needed to confirm safety as well as effectiveness.

To treat depression

Clinical studies produced conflicting results or were poorly designed, and one large study did not find benefit in major depressive disorder. More studies are needed to evaluate this use.

To treat hot flashes

A preliminary study suggests SAM-e is ineffective for this use.

To treat muscle pain

Older studies of SAM-e for fibromyalgia suggest some benefit, but larger studies are needed to confirm this.

To treat AIDS-related spinal cord disease

One study did not show significant benefits in this patient population

To treat Alzheimer’s disease

Studies that evaluate SAM-e without other supplements for Alzheimer’s disease are lacking.

SEIZURE CONTROL

S-adenosylmethionine (SAMe) is best known as a methyl donor in cellular metabolism, but it also has potential neuroprotective roles that could influence seizure control. While evidence is still preliminary, here’s how SAMe might help:

🔬 Mechanistic Pathways Relevant to Seizures

Methylation & Epigenetic Regulation

- SAMe is the body’s primary methyl donor, supporting DNA, RNA, and protein methylation.
- Epigenetic regulation of genes involved in neuronal excitability, GABA/glutamate balance, and inflammation may help stabilize seizure thresholds.

Glutathione Synthesis & Antioxidant Defense

- SAMe contributes to cysteine and glutathione production.
- By boosting glutathione, SAMe reduces oxidative stress, which is a known driver of seizure activity and neuronal damage.

Neurotransmitter Metabolism

- SAMe is involved in the synthesis and regulation of monoamines (dopamine, serotonin, norepinephrine).
- Balanced neurotransmitter metabolism may indirectly support seizure control, especially in comorbid mood disorders.

Anti-inflammatory Effects

- Through methylation-dependent pathways, SAMe can reduce pro-inflammatory cytokine expression.
- Since neuroinflammation contributes to epileptogenesis, this mechanism may be protective.

🧪 Evidence Landscape

Preclinical Studies

- Animal models suggest SAMe supplementation can reduce oxidative stress and protect neurons during excitotoxic events.
- Some studies show improved resilience against seizure-inducing agents, though results are not consistent across all models.

Human Data

- SAMe is widely studied for depression, liver disease, and osteoarthritis.
- No large-scale clinical trials yet confirm its efficacy in epilepsy. Its role remains theoretical and exploratory.

⚖️ Risk–Benefit Snapshot

Dimension	Potential Benefit	Risks / Gaps
Mechanistic Strengths	Epigenetic regulation, antioxidant defense, anti-inflammatory effects	Indirect action (not a direct GABAergic agent)
Evidence Base	Preclinical neuroprotection, strong data in oxidative stress	No epilepsy-specific human trials
Safety Profile	Generally well tolerated, used clinically for depression/liver disease	High doses may cause GI upset, insomnia, or interact with antidepressants
Clinical Utility	Possible adjunct for drug-resistant epilepsy with oxidative stress/inflammation	Needs controlled trials before clinical adoption

📌 Key Takeaway

SAMe could help control seizures indirectly by reducing oxidative stress, modulating inflammation, and influencing gene expression. It is not a frontline antiseizure agent, but may one day serve as an adjunctive therapy—especially in epilepsy subtypes linked to oxidative stress or metabolic dysfunction.

Per Sloan-Kettering:

Clinical Summary:

SAM-e is endogenously produced in the human body from adenosine triphosphate and methionine . It is involved in the formation of monoamine neurotransmitters such as serotonin and norepinephrine . Decreased SAM-e levels in cerebrospinal fluid are thought to contribute to the etiologies of depression and Alzheimer’s disease . SAM-e levels may also be decreased in chronic liver disease and AIDS-associated myelopathy . In the United States, SAM-e is marketed as a supplement to enhance mood, brain and neural function, joint mobility, and liver detoxification. It is also a prescription drug in other countries.

Preclinical data suggest that SAM-e may have antidepressive, neuroprotective , anti-inflammatory , and chondroprotective effects. Other models suggest liver injury can be exacerbated by depleted SAM-e levels, and that supplementation may have hepatoprotective effects.

In humans, data on whether SAM-e is an effective adjunct for major depressive disorder are mixed , and a large trial did not find benefit with SAM-e over escitalopram or placebo for major depressive disorder . Another study suggests benefit compared with escitalopram or placebo , but its therapeutic potential may be greater in men . A Cochrane review cites an absence of quality evidence , while a meta-analysis suggests adjunctive potential . Other preliminary data suggest SAM-e may improve memory related cognitive symptoms in depressed patients . However, studies that suggest cognitive benefits for patients with Alzheimer’s disease do not evaluate SAM-e in isolation.

Although results are mixed, a few clinical trials of SAM-e for osteoarthritis suggest benefit comparable with NSAIDs . For hot flashes, SAM-e was ineffective compared with historical placebo . It also did not significantly improve neurological measures in patients with AIDS-associated myelopathy . Preliminary trials suggest some benefit in fibromyalgia patients , but larger studies are needed.

Some trials have suggested benefit with oral SAM-e in patients with chronic liver disease . Addition of oral SAM-e to injected pegylated interferon alpha (pegIFN alpha) and oral ribavirin improved viral response in patients with chronic hepatitis C . Postoperative intravenous SAM-e therapy improved residual liver function in patients with cirrhosis . However, in patients with hepatitis C cirrhosis at elevated risk for hepatocellular carcinoma, oral SAM-e did not improve liver function, or reduce injury or oxidative stress . A small open-label study suggests oral SAM-e may be useful as adjunctive palliative therapy in patients with advanced biliary tract carcinoma . Other preliminary analyses suggest protective effects with SAM-e against chemotherapy-induced liver toxicity . Additional confirmatory studies are needed to assess efficacy and safety.

While generally well-tolerated, the therapeutic value of SAM-e in chronic liver disease is limited or yet to be determined. Because it is poorly absorbed, enteric-coated tablets are preferred. Outside the United States, parenteral formulations are used to treat fibromyalgia , osteoarthritis, and tendonitis as well as depression. However, patients with bipolar disorder or taking serotonergic medications including antidepressants should discuss any use of this supplement with their treating physician, as cases of mania and serotonin syndrome have been reported.

Mechanism of Action

SAM-e is endogenously produced from adenosine triphosphate and the amino acid methionine. It is a major, ubiquitous methyl donor to a wide variety of molecules , including catecholamines and other biogenic amines, fatty acids, neurotransmitters, nucleic acids, polysaccharides, porphyrins, proteins and membrane phospholipids. Homocysteine is formed through the transsulfuration pathway and is catabolized to cysteine and indirectly to glutathione.

In preclinical models, SAM-e protected against amyloid-beta-induced cellular injury by inhibiting oxidative stress and neuroinflammation . It also increased the endogenous antioxidant glutathione and potentiated antioxidant enzyme activity. Supplementation with SAM-e restores hepatic glutathione (GSH) deposits and attenuates liver injury . The mechanism by which SAM-e might treat depression is unknown, but increased synthesis of neurotransmitters such as serotonin, norepinephrine, and dopamine, may increase responsiveness of neurotransmitter receptors and fluidity of cell membranes in the production of phospholipids.